CTRI/2020/04/024655尚未招募2 期
A Randomized,Active-Controlled,Assessor-Blinded,Parallel Group Clinical Study to evaluate the safety and efficacy of Asgand and Brahmi in the Management of Qillat-e-Darqiyyat Asli (Primary Hypothyroidism) - PGJV
ational Research Institute of Unani Medicine for Skin Disorders Hyderabad0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of any gender
- •Patients in the age group between 19 and 60 years
- •Patients with Symptomatic Subclinical Primary Hypothyroidism
- •Patients with Clinical Primary Hypothyroidism
- •TSH ranging 5-10mg/dl
排除标准
- •Patients aged <19years or >60 years
- •Asymptomatic cases of Subclinical Primary Hypothyroidism
- •Severe/ complicated cases of Clinical Primary Hypothyroidism
- •Patients with Drug-induced Hypothyroidism
- •Patients on radiotherapy for head and neck region
- •ï?· Patients who have undergone thyroidectomy
- •ï?· Pregnant or Lactating Women
- •ï?· Significant Pulmonary/ Cardiovascular/ Hepatic/ Renal Diseases
- •ï?· Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies
- •ï?· Patients with Diabetes Mellitus
- •ï?· Patients with history of hypersensitivity to Asgand or Brahmi ï?· Patient not willing to attend treatment schedule regularly
研究者
相似试验
招募中
2 期
Clinical study for the treatment of white patches (vitiligo) with unani and allopathic medicineCTRI/2020/09/028107ational Research Institute of Unani medicine for Skin disorders
尚未招募
2 期
A comparative Clinical Study to evaluate the safety and efficacy of a unani formulation in the Management of Wajaâ??al-MafÄ?á¹£il (Rheumatoid Arthritis)CTRI/2020/03/024187ational Research Institute of Unani Medicine for Skin Disorders Hyderabad
尚未招募
3 期
A Phase III clinical study to evaluate efficacy and safety of GeneSys Insulin GlargineCTRI/2023/03/050804GeneSys Biologics Pvt. Ltd.
进行中（未招募）
1 期
A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other malignancies in Renal Transplanted Recipients with at least one SCC during the last 2 yearsSquamous cell carcinoma (SCC) and other malignancies in renal transplanted recipientsMedDRA version: 17.0Level: PTClassification code 10041823Term: Squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005481-35-DKppsala University Hospital220
进行中（未招募）
1 期
Clinical research study to learn about the effect and safety of different doses of FE 999302 when given as a single dose for final development of the eggs after ovarian stimulatioMedDRA version: 20.1Level: LLTClassification code 10016398Term: Female infertilitySystem Organ Class: 100000004872InfertilityEUCTR2022-000753-80-DKFerring Pharmaceuticals A/S500